New hope for Hard-to-Treat ovarian cancer: drug combo enters human testing

NCT ID NCT06856499

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether combining two drugs, Cirtuvivint and Olaparib, is safe for women with ovarian cancer that no longer responds to platinum chemotherapy. About 50 participants will take the medications on different schedules and visit the clinic regularly for checkups. The goal is to find the best dose and see how well the body tolerates the combination.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOID OVARIAN CANCER FALLOPIAN TUBE CANCER PRIMARY PERITONEAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CU Medicine Clinics
RECRUITING

Aurora, Colorado, 80045, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Universtiy of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••